Trauma, and Genital and Urethral Reconstruction.
Trauma, and Genital and Urethral Reconstruction.
复制标题
创伤、生殖器和尿道重建。
DOI:
10.1097/ju.0000000000002365
复制
发表时间:
2021
影响因子:
6.6
通讯作者:
S. Elliott
中科院分区:
文献类型:
--
作者:
S. Elliott
Editorial Comment: Herein, Smith et al report the results of a secondary analysis of a previously reported circumcision randomized controlled trial performed in Kenya on more than 2,700 men. In the original publication they (and others published around the same time) showed that circumcision reduces female-to-male HIV transmission by 50% e60%. 1e3 Herein, they demonstrate the benefit of circumcision in human papilloma virus (HPV) incident infection, HPV clearance and HPV reinfection among a subset of over 2,000 men in this same circumcision trial group who also had HPV testing. To be clear, all of these men were negative for HIV at baseline but about half were HPV positive, 35% with high-risk HPV serotypes. The results are positive, strong, durable over time and consistent across multiple outcomes measures. These findings are important because HPV (particularly subtype 16/18) is a risk factor for penile, cervical and anal cancer). Others have previously shown that male circumcision also reduces the rate of male-to-female HPV transmission. 4At 24 months, circumcised men had a 40% lower incidence of HPV infection and, supporting the concept validity, the benefit was seen in the glans, but not shaft specimens. This 40% was fairly consistent across all HPV serological subtypes. Incident infection was defined as a positive test among men who were negative for that serotype at baseline. Circumcised men also had a 35% lower HPV reinfection rate; this was defined as positive at baseline, followed by a negative test and then turning positive again. Circumcised men were also more likely to clear an infection, whether it was a prevalent infection present at baseline (HR of clearance 1.87) or an incident infection not present at baseline (HR of clearance 1.68). Again, this benefit was strong for both low-risk and high-risk serological subtypes.